1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (212) 390-6921
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Identification of genes that are regulated transcriptionally by Myc in childhood tumors
Article first published online: 8 JUL 2003
DOI: 10.1002/cncr.11584
Copyright © 2003 American Cancer Society
Additional Information
How to Cite
Raetz, E. A., Kim, M. K. H., Moos, P., Carlson, M., Bruggers, C., Hooper, D. K., Foot, L., Liu, T., Seeger, R. and Carroll, W. L. (2003), Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer, 98: 841–853. doi: 10.1002/cncr.11584
Publication History
- Issue published online: 1 AUG 2003
- Article first published online: 8 JUL 2003
- Manuscript Accepted: 16 MAY 2003
- Manuscript Revised: 14 MAY 2003
- Manuscript Received: 8 APR 2003
Funded by
- Mount Siani School of Medicine. Grant Number: R01 CA85767-03
- Cancer Center Support Grant. Grant Number: P30CA42014
- Huntsman Cancer Foundation
REFERENCES
- 1, , , . Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene. 1998; 17: 165–171.
- 2, . Myc oncogenes: the enigmatic family. Biochem J. 1996; 314: 713–721.
- 3, , . Contributions of Myc to tumorigenesis. Biochim Biophys Acta. 2002; 1602: 61–71.
- 4. Deconstructing myc. Genes Dev. 2001; 15: 2023–2030.
- 5, . The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J. 1998; 12: 633–651.
- 6, , , , . c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J. 1994; 13: 4070–4079.
- 7, , , , . A link between c-Myc-mediated transcriptional repression and neoplastic transformation. J Clin Invest. 1996; 97: 1687–1695.
- 8, . Myc-mediated transformation: the repression connection. Oncogene. 1999; 18: 2925–2933.
- 9, , , et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev. 2000; 14: 1390–1399.
- 10, , , , . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224: 1121–1124.
- 11, , , et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985; 313: 1111–1116.
- 12, , , , , . Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene. 1996; 13: 803–812.
- 13, , , , . Altered growth and phenotype in clonal mycN transfectants of the SK-N-SH neuroblastoma cell line. Int J Cancer. 1994; 59: 141–148.Direct Link:
- 14, , , , , . Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res. 1990; 50: 4411–4416.
- 15, , . Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture. Nature. 1985; 316: 160–162.
- 16, , , et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol. 2000; 18: 3604–3613.
- 17, . New Myc-interacting proteins: a second Myc network emerges. Oncogene. 1999; 18: 2942–2954.
- 18, , , . The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000; 16: 653–699.
- 19, , , et al. Expression of the c-Myc protein in childhood medulloblastoma. J Pediatr Hematol Oncol. 1998; 20: 18–25.
- 20, , , et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res. 2001; 7: 2425–2433.
- 21, , , et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer. 2000; 89: 395–402.Direct Link:
- 22, , , et al. Diversity of the apoptotic response to chemotherapy in childhood leukemia. Leukemia. 2002; 16: 223–232.
- 23, , , et al. Identification of gene expression profiles that segregate patients with childhood leukemia. Clin Cancer Res. 2002; 8: 3118–3130.
- 24, , , et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001; 344: 539–548.
- 25, , , et al. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod Pathol. 2002; 15: 159–166.
- 26, , , et al. Successful treatment of Stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol. 1998; 16: 1256–1264.
- 27, , , et al. Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med Pediatr Oncol. 2001; 36: 32–36.Direct Link:
- 28, , , et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the Pediatric Oncology Group experience—a Pediatric Oncology Group study. J Clin Oncol. 1998; 16: 2007–2017.
- 29, , , et al. Biologic factors determine prognosis in infants with Stage IV neuroblastoma: a prospective Children's Cancer Group study. J Clin Oncol. 2000; 18: 1260–1268.
- 30, , , et al. Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma. Med Pediatr Oncol. 2000; 35: 647–650.Direct Link:
- 31, , , et al. Biologic variables in the outcome of Stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group study. J Clin Oncol. 2000; 18: 18–26.
- 32, , , et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999; 341: 1165–1173.
- 33, . Molecular biology of neuroblastoma. J Clin Oncol. 1999; 17: 2264–2279.
- 34, , , et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol. 1997; 15: 1171–1182.
- 35, , , et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991; 9: 581–591.
- 36, , , , . Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol. 1998; 16: 3286–3294.
- 37, , , et al. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 2001; 20: 1383–1393.
- 38, , , et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A. 2000; 97: 3260–3265.
- 39, , , et al. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res. 2001; 29: 397–406.
- 40, , , et al. Gene-target recognition among members of the myc superfamily and implications for oncogenesis. Nat Genet. 2000; 24: 113–119.
- 41, , , et al. Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res. 2000; 60: 5922–5928.
- 42, . A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors. Oncogene. 2001; 20: 4984–4994.
- 43, , . Myc family oncoproteins function through a common pathway to transform normal cells in culture: cross-interference by Max and trans-acting dominant mutants. Genes Dev. 1992; 6: 1480–1492.
- 44, , . Direct recruitment of N-myc to target gene promoters. Mol Carcinog. 2000; 29: 76–86.Direct Link:
- 45, , , , . Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature. 2000; 407: 592–598.
- 46, , , et al. Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res. 2002; 62: 301–306.
- 47, , , et al. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Cancer Res. 2003; 63: 1631–1635.
- 48, , , , , . ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value. Oncogene. 2003; 22: 456–460.
- 49, , , . Direct activation of RNA polymerase III transcription by c-Myc. Nature. 2003; 421: 290–294.
- 50. The role of c-myc in cellular growth control. Oncogene. 1999; 18: 2988–2996.
- 51, , , et al. The receptor for ciliary neurotrophic factor. Science. 1991; 253: 59–63.
- 52, , , et al. In vivo localization and characterization of functional ciliary neurotrophic factor receptors which utilize JAK-STAT signaling. Neuroscience. 2000; 99: 761–772.
- 53
- 54, , , . Signaling pathway of ciliary neurotrophic factor in neuroblastoma cell lines. Med Pediatr Oncol. 2001; 36: 118–121.Direct Link:
- 55, , , , . Effects of stathmin inhibition on the mitotic spindle. J Cell Sci. 2001; 114: 909–916.
- 56. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol. 2002; 14: 18–24.
- 57, , , , . Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase. J Biol Chem. 1994; 269: 10312–10318.
- 58, , , . Taxol and anti-stathmin therapy: a synergistic combination that targets the mitotic spindle. Cancer Res. 2000; 60: 3537–3541.
- 59, , . Development of ribozymes that target stathmin, a major regulator of the mitotic spindle. Antisense Nucleic Acid Drug Dev. 2001; 11: 41–49.
- 60, . Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 2000; 184: 1–16.Direct Link:
- 61, , . Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002; 21: 2245–2252.
- 62, . Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis. 2001; 6: 479–482.
- 63, , . Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res. 1998; 58: 2310–2315.
- 64, , , , . Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer. 1999; 79: 1347–1355.
- 65, , , , . Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem. 2002; 277: 13787–13795.
- 66, , , et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999; 59: 798–802.
- 67
- 68. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999; 19: 1–11.
- 69, . Myc target genes. Trends Biochem Sci. 1997; 22: 177–181.
- 70National Center for Biotechnology Information. UniGene [database online]. Available from URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene
- 71National Center for Biotechnology Information. GenBank [database online]. Available from URL: http://www.ncbi.nih.gov/Genbank